Researchers conducted a 6-year longitudinal cohort study that analyzed the impact of glucocorticoid intake at varying doses
Researchers analyzed corticosteroids or immunosuppressive therapy tapering across 14,808 patient-visits among 3002 patients with systemic lupus erythematosus.
Patients in the sarilumab vs placebo group achieved sustained remission of polymyalgia rheumatica at higher rates.
At 18 months, patients who underwent an intensive diet and exercise regimen had a body weight of 10.9kg (24.0 lb) compared with control participants who had a body weight of 2.7kg.
Vilobelimab is a monoclonal antibody which works to reduce the level of complement split factor C5a by preserving the membrane attack complex.
The first group received high-dose lirentelimab for 24 weeks. The second group received low-dose lirentelimab, while the placebo group received 6 monthly infusions during the 24-week study.
Patients taking tradipitant demonstrated significant improvements in nausea compared with placebo.
Biologics target inflammatory pathways, allowing for mucosal healing with the end goal of achieving clinical remission.
After 6 months following treatment, 90.5% (38 of 42) responders to RBX2660 remained recurrence-free, whereas 85% (17 of 20) patients in the placebo group remained recurrence-free.
Patients who underwent colonoscopy after 7 days following their diverticular bleeding episodes demonstrated a significantly higher risk of 30-day mortality.
